# Genetic Testing Market

> Genetic Testing Market Research Report: Size, Share, Trend Analysis By Applications (Prenatal Testing, Newborn Screening, Carrier Testing, Diagnostic Testing, Predictive Testing), By Types (Single Gene Tests, Panel Tests, Whole Exome Sequencing, Whole Genome Sequencing, Non-Invasive Prenatal Testing), By Service Type (Laboratory Services, Diagnostic Services, Consultation Services), By End Users (Hospitals, Clinical Laboratories, Research Institutions, Homecare Settings) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 18.82%
- **2024:** $ 13.3 Billion
- **2025:** $ 15.8 Billion
- **2035:** $ 88.64 Billion
- **Key Players:** Companies such as Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Abbott Laboratories (US), Myriad Genetics (US), 23andMe (US), Genomic Health (US), Fulgent Genetics (US), Natera (US) are some of the major participants in the global market.

**Report ID:** MRFR/HC/1477-CR · **Pages:** 150 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** July 22, 2026

**URL:** https://www.marketresearchfuture.com/reports/genetic-testing-market-2009

---

## Market Summary

The Global Genetic Testing Market size was valued at USD 13.3 Billion in 2024, and the market is projected to grow from USD 15.8 Billion in 2025 to USD 88.64 Billion by 2035, registering a CAGR of 18.82% during the forecast period 2025–2035. North America led the market in 2024 with over 45.11% share, generating around USD 6 Billion in revenue.
 
The growing adoption of preventive healthcare is accelerating the Genetic Testing Market, as individuals and healthcare providers increasingly use genetic insights for early disease risk identification, personalized treatment planning, and improved clinical decision-making.
 
According to the WHO Data Portal, noncommunicable diseases account for approximately 74% of global deaths annually, highlighting the rising need for early detection and preventive healthcare approaches such as genetic testing to identify disease risks and support timely interventions.

## Market Drivers

### Rising Prevalence of Genetic Disorders

The increasing incidence of genetic disorders is a primary driver for the Genetic Testing Industry. Conditions such as [cystic fibrosis](https://www.marketresearchfuture.com/reports/cystic-fibrosis-market-1825), sickle cell anemia, and various hereditary cancers are becoming more prevalent, prompting a greater need for genetic testing.
 
According to recent estimates, approximately 1 in 33 babies is born with a genetic disorder, which underscores the urgency for early detection and intervention. This trend is likely to propel the demand for genetic testing services, as healthcare providers and patients seek to understand genetic risks and make informed decisions. The market is thus positioned to expand significantly as awareness of genetic disorders grows, leading to increased testing and subsequent treatment options.
 

- Research published through PubMed indicates that rare genetic diseases collectively affect approximately 300 million people worldwide, highlighting significant demand for early diagnosis and genetic screening. Increasing recognition of inherited disorders is encouraging healthcare providers to adopt genetic testing for improved disease identification and management.

### Advancements in Sequencing Technologies

Technological advancements in sequencing technologies are revolutionizing the Genetic Testing Industry. Innovations such as next-generation sequencing (NGS) have dramatically reduced the cost and time required for genetic testing, making it more accessible to a wider population. The cost of sequencing a human genome has plummeted from thousands of dollars to a few hundred, facilitating the growth of genetic testing services.
 
As these technologies continue to evolve, they are likely to enhance the accuracy and efficiency of genetic tests, further driving market expansion. The market stands to gain from these advancements, as healthcare providers increasingly adopt cutting-edge technologies to meet the rising demand for comprehensive genetic testing.
 

- The Institute for Health Metrics and Evaluation (IHME) reports increasing global healthcare data availability through genomic and advanced diagnostic technologies. Growing investments in precision healthcare infrastructure are supporting the adoption of next-generation sequencing, enabling faster and more comprehensive genetic analysis across clinical applications.

### Regulatory Support and Reimbursement Policies

Supportive regulatory frameworks and favorable reimbursement policies are crucial drivers for the Genetic Testing Industry. Governments and health organizations are increasingly recognizing the value of genetic testing in preventive healthcare and disease management. As a result, many countries are implementing policies that facilitate access to genetic testing services.
 
Additionally, insurance companies are beginning to cover genetic tests, which alleviates the financial burden on patients. This trend is expected to encourage more individuals to seek genetic testing, thereby expanding the market. The market is likely to experience growth as these supportive measures continue to evolve, promoting wider adoption of genetic testing across various demographics.

### Artificial Intelligence (AI) and Machine Learning

Artificial Intelligence (AI) and Machine Learning (ML) are rapidly reshaping the landscape of early cancer diagnosis and genetic testing by enabling faster, more accurate, and highly scalable analysis of complex clinical and molecular data. These technologies leverage sophisticated algorithms to interpret large datasets, including genomic sequences from next-generation sequencing, circulating tumor DNA (ctDNA) from liquid biopsies, histopathology images, and multi-omic profiles. By detecting subtle patterns and correlations that may be missed by human analysis, AI enhances the sensitivity and specificity of cancer detection, facilitating earlier diagnosis and better risk stratification.
 
In practical applications, AI-driven platforms are used to automate image analysis in radiology and pathology, predict cancer risk based on genetic and clinical data, and prioritize patients for further testing or treatment. For example, AI algorithms can analyze sequencing data from multi-gene panels or liquid biopsy assays to identify clinically relevant mutations, detect tumor heterogeneity, and track disease progression over time. Machine learning models also improve multi-cancer early detection (MCED) test performance, refining algorithms that distinguish cancer signals from normal genetic variation. The adoption of AI and ML is further accelerating through integration with cloud computing and digital health platforms, enabling remote analysis, real-time interpretation, and population-level screening initiatives.
 
Companies like GRAIL, Guardant Health, and Tempus are leveraging AI in combination with genomic and molecular diagnostics to provide predictive insights that guide personalized treatment planning and early intervention strategies. AI and ML are considered critical enablers of next-generation diagnostics, driving the scalability, efficiency, and precision of early cancer detection workflows. These technologies not only reduce human error and diagnostic turnaround times but also create opportunities for cost optimization and broader market adoption, particularly in large-scale screening programs. AI-integrated diagnostic solutions will increasingly become the standard of care in both developed and emerging markets, complementing traditional laboratory and sequencing technologies while accelerating the shift toward precision and preventive oncology.

### Growing Awareness and Acceptance of Genetic Testing

Public awareness and acceptance of genetic testing are on the rise, significantly influencing the Genetic Testing Industry. Educational campaigns and media coverage have played a crucial role in demystifying genetic testing, leading to increased consumer interest. Surveys indicate that a substantial percentage of individuals are now more willing to undergo genetic testing for both health and ancestry purposes.
 
This shift in perception is likely to drive market growth, as more people seek out testing services to gain insights into their genetic predispositions. The market is thus expected to benefit from this trend, with a projected increase in the number of tests conducted annually, reflecting a broader societal acceptance of genetic information.

### Integration of Genetic Testing in Personalized Medicine

The integration of genetic testing into personalized medicine is transforming the landscape of healthcare, thereby driving the Genetic Testing Industry. Personalized medicine tailors treatment plans based on an individual's genetic makeup, enhancing the efficacy of therapies. As healthcare systems increasingly adopt this approach, the demand for genetic testing is expected to rise.
 
For instance, pharmacogenomics, which studies how genes affect a person's response to drugs, is gaining traction. This shift towards personalized treatment strategies is projected to contribute to a market growth rate of over 10% annually in the coming years. Consequently, the market is likely to see a surge in investments and innovations aimed at developing more precise testing methodologies.

## Future Outlook

The Genetic Testing Market size is projected to reach USD 88.64 Billion by 2035, growing at a CAGR of 18.82%, driven by technological advancements, increasing consumer awareness, and rising demand for personalized medicine.

**New opportunities:**

- Expansion of direct-to-consumer genetic testing services Development of AI-driven genetic analysis platforms Partnerships with healthcare providers for integrated testing solutions

By 2035, the Genetic Testing Market is expected to be a pivotal component of personalized healthcare.

## Segment Insights

### By Application: Prenatal Testing (Largest) vs. Newborn Screening (Fastest-Growing)

The market showcases significant distribution among various applications, with Prenatal Testing leading as the largest segment, accounting for 32% share. This application has garnered substantial attention due to rising awareness around maternal health and the importance of genetic information in predicting potential health concerns in fetuses. Conversely, Newborn Screening has emerged rapidly, driven by healthcare policies advocating for thorough screening at birth to ensure early interventions and treatments, thus significantly contributing to the overall market dynamics. Current growth trends indicate a robust demand for genetic testing applications, primarily propelled by advancements in technology and increasing investments in healthcare infrastructure. The need for enhanced diagnostic capabilities and the growing acceptance of genetic testing in preventive healthcare are key drivers. Furthermore, as personalized medicine gains traction, applications like Carrier Testing and Predictive Testing continue to draw interest, indicating a holistic evolution in personal health management and disease prevention strategies.

Natera has strengthened prenatal genetic testing adoption through its Panorama Non-Invasive Prenatal Test (NIPT), which analyzes fetal DNA from maternal blood samples. The company has processed millions of tests globally, supporting early detection of chromosomal abnormalities and increasing adoption of non-invasive prenatal screening solutions.

### By Type: Panel Tests (Largest) vs. Whole Genome Sequencing (Fastest-Growing)

The distribution of the Genetic Testing Market share of 38% among different types of genetic tests reveals that Panel Tests dominate due to their comprehensive nature and ability to screen for multiple conditions simultaneously. Single Gene Tests also hold a significant share, serving specific diagnostic purposes, while Whole Exome Sequencing and Non-Invasive Prenatal Testing follow closely, appealing to different consumer needs. Whole Genome Sequencing, though smaller currently, is emerging as a powerful tool for extensive genetic insights, gaining traction among consumers and healthcare providers alike.

Fulgent Genetics has expanded its genetic testing portfolio with comprehensive panel-based testing solutions covering thousands of genetic conditions. The company’s broad testing menu supports clinicians in diagnosing inherited disorders efficiently, improving accessibility to advanced genomic testing services across multiple healthcare applications.

### By Service Type: Laboratory Services (Largest) vs. Consultation Services (Fastest-Growing)

The distribution of market share among service types reveals that Laboratory Services dominate significantly due to their foundational role in the testing process. This segment includes a wide range of testing methodologies, including [DNA sequencing](https://www.marketresearchfuture.com/reports/dna-sequencing-market-5774) and genome analysis, which are essential for accurate diagnoses. Diagnostic Services also hold a considerable share of 55% but are often integrated with laboratory offerings, while Consultation Services, although smaller in share, are rapidly gaining traction as patients seek personalized guidance and support throughout the genetic testing journey.

Genomic Health, through its genomic diagnostic services, has supported personalized cancer treatment decisions with genomic testing solutions. Its Oncotype DX platform has been used in more than 2 million patients worldwide, demonstrating the growing importance of laboratory-based genetic testing services.

### By End User: Hospitals (Largest) vs. Clinical Laboratories (Fastest-Growing)

Hospitals hold the largest share of the Genetic Testing Market, accounting for 42% among end users, attributed to their comprehensive patient care capabilities and integration of advanced testing technologies. Clinical laboratories follow closely behind, focusing on specific testing solutions that cater to diverse patient needs. Research institutions and homecare settings contribute to the market but remain smaller in comparison, serving niche segments of the population with specialized tests and services.

Abbott Laboratories continues expanding molecular diagnostic capabilities through advanced laboratory testing solutions used by hospitals and healthcare networks globally. Its diagnostic technologies support faster disease detection and clinical decision-making, strengthening hospital adoption of genetic and molecular testing solutions.

## Regional Market Share Analysis

### North America : Leading Innovation and Adoption

North America leads in the Genetic Testing Market Size, accounting for over 45.11% of the global revenue in 2024, driven by advanced healthcare infrastructure, high consumer awareness, and significant investments in research and development. The demand for personalized medicine and preventive healthcare is propelling growth, alongside supportive regulatory frameworks that encourage innovation in genetic testing technologies.

- Myriad Genetics has strengthened the North American genetic testing market through advanced hereditary cancer testing solutions. The company’s genetic testing platforms have supported millions of patients by identifying inherited cancer risks, improving preventive healthcare strategies and supporting personalized treatment decisions.

The market for genetic testing USA is the primary contributor, with key players like Illumina, Thermo Fisher Scientific, and Myriad Genetics leading the market. The competitive landscape is characterized by rapid technological advancements and collaborations among companies and research institutions. Canada also plays a significant role, focusing on expanding access to genetic testing services and enhancing public health initiatives.

### Europe : Regulatory Frameworks Driving Growth

Europe Genetic Testing Market size was valued at USD 3.99 Billion in 2024, making it the second-largest regional market with a 30% share. The region benefits from stringent regulatory frameworks that ensure the safety and efficacy of genetic tests, alongside increasing public awareness and acceptance of genetic testing.

- The European Medicines Agency continues supporting genomic medicine development through regulatory frameworks for advanced diagnostics and personalized healthcare. Increasing approvals and regulatory guidance for innovative molecular diagnostic technologies are improving confidence in genetic testing adoption across European healthcare systems.

Countries like Germany and the UK are at the forefront, with supportive policies that promote innovation and accessibility in genetic healthcare. Germany leads the market, followed closely by the UK and France, with a competitive landscape featuring major players like Roche and Abbott Laboratories. The presence of advanced research institutions and a strong focus on personalized medicine are key drivers. Collaborative efforts between public and private sectors are enhancing the development and distribution of genetic testing services across Europe.

### Asia-Pacific : Rapid Growth and Adoption

Asia-Pacific is rapidly emerging as a significant player in the genetic testing market, holding around 20% of the global share. The region is driven by increasing healthcare expenditure, rising awareness of genetic disorders, and advancements in technology. Countries like China and India are leading the charge, with government initiatives aimed at enhancing healthcare access and promoting genetic research and testing services.

China is the largest market in the region, supported by a growing population and increasing demand for [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937). India follows closely, with a burgeoning biotechnology sector and a focus on affordable genetic testing solutions. The competitive landscape is evolving, with both local and international players, including Fulgent Genetics and Natera, striving to capture market share through innovative offerings.

### Middle East and Africa : Untapped Potential in Healthcare

The Middle East and Africa region is gradually recognizing the potential of genetic testing, currently holding about 5% of the global market share. The growth is driven by increasing healthcare investments, rising awareness of genetic diseases, and a push towards personalized medicine. Countries like South Africa and the UAE are leading the way, with initiatives aimed at improving healthcare infrastructure and access to genetic testing services.

South Africa is the largest market in the region, with a growing number of private and public sector collaborations enhancing the availability of genetic testing. The UAE is also emerging as a hub for genetic research and testing, supported by government initiatives. The competitive landscape is characterized by a mix of local and international players, focusing on expanding their services to meet the growing demand.

## Competitive Benchmarking

The Genetic Testing Market is currently characterized by a dynamic competitive landscape, driven by rapid technological advancements and increasing consumer demand for personalized healthcare solutions. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Myriad Genetics (US) are at the forefront, each adopting distinct strategies to enhance their market positioning.
 
Illumina (US) focuses on innovation in sequencing technology, aiming to lower costs and improve accessibility, while Thermo Fisher Scientific (US) emphasizes a broad portfolio of genetic testing solutions, catering to both clinical and research applications. Myriad Genetics (US) is strategically positioning itself through partnerships and acquisitions to expand its genetic testing capabilities, particularly in oncology, thereby shaping a competitive environment that is increasingly collaborative and innovation-driven.
 
In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market appears moderately fragmented, with a mix of established players and emerging companies vying for market share. The collective influence of these key players fosters a competitive structure that encourages innovation and rapid advancements in genetic testing technologies.
 
In August Illumina (US) announced a strategic partnership with a leading healthcare provider to integrate its genomic sequencing technology into routine clinical practice. This collaboration is poised to enhance patient access to advanced genetic testing, thereby reinforcing Illumina's position as a leader in the market. The strategic importance of this partnership lies in its potential to drive adoption of genomic testing in mainstream healthcare, aligning with the growing trend towards personalized medicine.
 
In September Myriad Genetics (US) launched a new genetic test aimed at identifying hereditary cancer risks, which is expected to significantly expand its market reach. This initiative underscores Myriad's commitment to innovation and its focus on oncology, a sector that is increasingly prioritized in genetic testing. The introduction of this test not only enhances Myriad's product offerings but also positions the company to capture a larger share of the growing demand for cancer-related genetic testing.
 
In October Thermo Fisher Scientific (US) unveiled a new digital platform designed to streamline genetic testing workflows for laboratories. This platform integrates advanced analytics and AI capabilities, which could potentially transform laboratory operations and improve turnaround times for test results. The strategic importance of this development lies in its ability to enhance operational efficiency and support laboratories in meeting the increasing demand for genetic testing services.
 
As of October current competitive trends in the market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances among key players are shaping the landscape, fostering innovation and collaboration. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological innovation, enhanced service delivery, and supply chain reliability, reflecting the industry's shift towards more sophisticated and personalized healthcare solutions.

## Recent News & Developments

**Helix BioPharma Corp.:(June-2025)**

**Helix BioPharma Corp. Announces CFO Appointment to Support Strategic Growth and Upcoming Milestones:** Indicates corporate restructuring and focus on future growth.

**Guardant Health: (June-2025)**

**FDA Grants Breakthrough Device Designation to Guardant Health's Shield MCD Test:** This is a significant regulatory milestone, accelerating the review process for their multi-cancer detection blood test.

**Invitae: (May -2025)**

**Labcorp Acquiring Invitae Assets for $239M:** This significant development indicates a major restructuring for Invitae, with parts of its business being acquired by Labcorp. This follows Invitae's filing for Chapter 11 bankruptcy protection.

The Global Genetic Testing Market has recently witnessed notable developments, including increased demand for genetic testing services driven by advances in [precision medicine](https://www.marketresearchfuture.com/reports/precision-medicine-market-925) and personalized healthcare. In October 2023, Myriad Genetics announced the launch of its new correlative testing platform aimed at enhancing patient care in oncology.

Additionally, in September 2023, Abbott Laboratories expanded its genetic testing portfolio with new tests for hereditary cancer risk, targeting a growing focus on preventative health measures. In terms of mergers and acquisitions, Invitae acquired ArcherDX in September 2020, a significant move aimed at enhancing its [molecular diagnostics](https://www.marketresearchfuture.com/reports/molecular-diagnostics-market-1171) capabilities.

Similarly, 23andMe announced a partnership with GlaxoSmithKline in July 2023, expanding their collaborative efforts in genetic research to develop new therapies. The market has seen a surge in valuation, with companies like Illumina and Thermo Fisher Scientific reporting robust quarterly earnings due to increased adoption of genetic testing technologies across various healthcare settings.

Over the last couple of years, the market has observed a shift towards home-based genetic testing services, with Color Genomics leveraging digital platforms to reach consumers more effectively. The growing awareness of genetic diseases and advancements in genomic technologies continue to shape the ongoing transformation in this sector.

## Report Scope

| MARKET SIZE 2024 | 13.3(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 15.8(USD Billion) |
| MARKET SIZE 2035 | 88.64(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.82% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Abbott Laboratories (US), Myriad Genetics (US), 23andMe (US), Genomic Health (US), Fulgent Genetics (US), Natera (US) |
| Segments Covered | Applications, Types, Service Type, End Users, Regional |
| Key Market Opportunities | Advancements in personalized medicine drive demand for innovative solutions in the market. |
| Key Market Dynamics | Rising consumer demand for personalized medicine drives innovation and competition in the market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Genetic Testing Market as of 2024?**
A: The Genetic Testing Market was valued at 13.3 USD Billion in 2024.

**Q: What is the projected market valuation for the Genetic Testing Market in 2035?**
A: The market is projected to reach 88.64 USD Billion by 2035.

**Q: What is the expected CAGR for the Genetic Testing Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Genetic Testing Market during 2025 - 2035 is 18.82%.

**Q: Which companies are considered key players in the Genetic Testing Market?**
A: Key players in the market include Illumina, Thermo Fisher Scientific, Roche, Abbott Laboratories, Myriad Genetics, 23andMe, Genomic Health, Fulgent Genetics, and Natera.

**Q: What are the main application segments of the Genetic Testing Market?**
A: The main application segments include Prenatal Testing, Newborn Screening, Carrier Testing, Diagnostic Testing, and Predictive Testing.

**Q: How does the market size for Diagnostic Testing compare to other application segments?**
A: Diagnostic Testing had a valuation of 3.5 USD Billion in 2024, with a projected growth to 25.0 USD Billion by 2035.

**Q: What types of genetic tests are included in the market analysis?**
A: The types of genetic tests include Single Gene Tests, Panel Tests, Whole Exome Sequencing, Whole Genome Sequencing, and Non-Invasive Prenatal Testing.

**Q: What is the projected market size for Whole Genome Sequencing by 2035?**
A: Whole Genome Sequencing is projected to grow from 3.0 USD Billion in 2024 to 25.0 USD Billion by 2035.

**Q: Which service types are analyzed within the Genetic Testing Market?**
A: Service types analyzed include Laboratory Services, Diagnostic Services, and Consultation Services.

**Q: What is the expected growth for Clinical Laboratories as an end user in the Genetic Testing Market?**
A: Clinical Laboratories are expected to grow from 4.0 USD Billion in 2024 to 30.0 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/genetic-testing-market-2009*